Search Results
Your search for ,foR matches 32399 pages
Showing 18751 - 18800ESMO 2017: Patients With High-Risk Prostate Cancer May Benefit From Addition of Docetaxel or Abiraterone/Prednisolone to Long-Term Hormone Therapy
Patients with high-risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (LBA31_PR). Long-term hormone therapy...
ESMO 2017: New Data Confirms Superiority of Docetaxel-Based Triplet Therapy in Esophagogastric Cancer
The superiority of docetaxel-based triplet therapy over standard of care in patients with resectable esophagogastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA27_PR)....
ESMO 2017: DNA Sequencing Could Open Up New Drug Indications for Patients With Rare Cancers
Due to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers but who carry the same genetic mutations. The first results of a multidrug and multitumor clinical trial (Abstract...
Bonnie S. Glisson, MD, on HPV-16+ Cancer: Study Results
Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-16+ cancer (Abstract 1136O).
Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).
ESMO 2017: Combination Targeted Adjuvant Therapy Doubles Relapse-Free Survival in Stage III Melanoma
Combination targeted adjuvant therapy with dabrafenib (Tafinlar) and trametinib (Mekinist) doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented on September 11 at the European Society for Medical Oncology ...
ESMO 2017: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma
Adjuvant nivolumab (Opdivo) is superior to standard-of-care ipilimumab (Yervoy) in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented on September 11 at the European Society for Medical...
Remnant Liver Ischemia and Cancer-Specific Survival After Resection of Colorectal Liver Metastases
In a single-center experience reported by Yamashita et al in JAMA Surgery, postoperative remnant liver ischemia of grade ≥ 2 was associated with worse cancer-specific survival after resection of colorectal liver metastases. Study Details The retrospective analysis included 202 patients who...
Alzheimer’s Disease Risk in Medicare Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
As reported by Baik et al in the Journal of Clinical Oncology, Medicare patients who received androgen-deprivation therapy for prostate cancer do not appear to be at increased risk for Alzheimer’s disease and may have an extremely small increased risk for dementia. Study Details The study...
Adding First-Line Ipilimumab to Paclitaxel/Carboplatin in Advanced Squamous NSCLC
In a phase III trial reported by Govindan et al in the Journal of Clinical Oncology, the addition of first-line ipilimumab (Yervoy) to paclitaxel/carboplatin did not improve overall survival in patients with advanced squamous non–small cell lung cancer (NSCLC). Study Details In the...
ESMO 2017: Some Stroke Survivors May Have Underlying Cancer
Some stroke survivors may have underlying cancer, according to an observational study presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 1412P_PR). “Postmortem studies have suggested that cancer can develop after a stroke, but the magnitude of...
ESMO 2017: Rucaparib Boosts Progression-Free Survival in BRCA-Mutant Recurrent Ovarian Cancer
Rucaparib (Rubraca) maintenance therapy increases progression-free survival in BRCA-mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA40_PR). Most...
ESMO 2017: MIRO Trial: 3-Year Outcomes Favor Laparoscopic Surgery for Esophageal Cancer
Patients requiring surgery for esophageal cancer fare better after undergoing a hybrid minimally invasive esophagostomy compared to an open esophagostomy, according to long-term results of the MIRO trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract ...
ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer
Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in...
ESMO 2017: ALEX and ALUR Trials: Alectinib Shows CNS Benefit in ALK-Positive NSCLC
Data from two separate phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid show the particular central nervous system (CNS) activity of alectinib (Alecensa) in patients with advanced non–small cell lung cancer involving a mutation of the...
Cora N. Sternberg, MD, on Prostate Cancer Treatment Findings: Expert Perspective
Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized prostate cancer patients who relapsed after radical prostatectomy and/or radiotherapy (Abstracts...
Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial
Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).
Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial
Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstract LBA7).
Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial
Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.
Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine plus oxaliplatin) for biliary tract cancer (LBA29).
Cabozantinib Salvage Therapy in Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer
A phase II study has shown that cabozantinib (Cometriq) produces responses in patients with tyrosine kinase inhibitor–refractory differentiated thyroid cancer. The findings were reported by Cabanillas et al in the Journal of Clinical Oncology. MET plays a role in vascular endothelial growth...
ESMO 2017: Phase III IFCT-0302 Trial Assesses Minimal vs CT Scan–Based Follow-up for Completely Resected NSCLC
The optimal follow-up protocol for patients with completely resected non–small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid, did not show a difference in overall survival...
ESMO 2017: MINDACT Study in Early-Stage Breast Cancer Shows Even Small Tumors Can Be Aggressive
Even small tumors in the breast can be aggressive, according to a study in patients with early-stage breast cancer presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 150O_PR). Researchers found that 24% of small tumors were aggressive, and patients...
ESMO 2017: Overuse of Tumor Marker Tests in Primary and Secondary Care
The vast majority of tumor marker tests in primary and secondary care are not necessary, according to a study presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 1410P_PR). The tests assisted with a cancer diagnosis in just 2% of patients....
Guadecitabine in Treatment-Naive Older Patients With Acute Myeloid Leukemia
The results of a phase II trial have shown high activity of guadecitabine, a next-generation hypomethylating drug, in treatment-naive older patients with acute myeloid leukemia. The findings were reported in The Lancet Oncology by Kantarjian et al. Guadecitabine has a longer half-life and exposure...
Health-Related Quality of Life With Everolimus vs Placebo in Patients With Neuroendocrine Tumors
As reported in The Lancet Oncology by Pavel et al, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...
Association of Supplemental Vitamin B Use and Lung Cancer in VITAL Cohort
In a study reported in the Journal of Clinical Oncology, Brasky et al found that the use of individual source supplemental vitamins B6 and B12 was associated with an increased risk of lung cancer among men in the Vitamins and Lifestyle (VITAL) cohort. Several B vitamins, including B6, B9 (folate),...
Immunologic Biomarkers and Survival in Third-Generation CAR T-Cell Therapy
A phase I/IIa study investigating the safety and effectiveness of a third-generation CD19-specific chimeric antigen receptor (CAR) T-cell therapy in patients with lymphoma or leukemia has found that the treatment led to a complete response in 6 of the 15 patients in the study and that overall...
Study Finds Gut Microbes May Promote Immune Responses Against Colorectal Cancer
Colorectal cancer is the third leading cancer-related cause of death worldwide, accounting for 774,000 deaths in 2015, according to the World Health Organization. Now, a study presented at the third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival, ...
FDA Pilot Program Aims to Encourage Students to Pursue STEM Careers
When I was in high school, I spent summers working as a restaurant dishwasher, grocery store stock boy, and gardener in northwest Indiana. The idea of spending those weeks learning about science and medicine would not have been an option for me at that time. Yet it is precisely those students who...
Conquer Cancer Foundation and ASCO International Development and Education Award
Applications Being Accepted Through October 31, 2017 THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) provides support for early-career oncologists in low-and middle-income countries and facilitates the sharing of knowledge between these oncologists and ASCO members. The program pairs IDEA ...
Relationship Between Molecular Subtypes of Gastric Cancer and Prognosis
In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability, genomically stable, and chromosomal instability. However, their clinical significance is unknown. Now, a study by Bo Hwa Sohn, PhD,...
Dinutuximab vs Temsirolimus in Combination Therapy for Children With Resistant Neuroblastoma
A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab (Unituxin) plus irinotecan/temozolomide as a regimen to be further evaluated in the treatment of pediatric patients with refractory or relapsed neuroblastoma. Study results were...
Douglas R. Lowy, MD, and John T. Schiller, PhD, to Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) will receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize,...
Zika Virus Shows Oncolytic Activity Against Glioblastoma Stem Cells in Preclinical Trial
Although Zika virus causes devastating damage to the brains of developing fetuses, it someday may prove to be an effective treatment for glioblastoma. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine showed that...
Financial Burden Among Survivors of Childhood Cancer
Findings from the Childhood Cancer Survivor Study, reported in the Journal of Clinical Oncology by Nipp et al, indicate that childhood cancer survivors are more likely than unaffected siblings to spend a higher percentage of income on out-of-pocket medical costs, potentially leading to reduced use...
CMS Grants Disaster Exceptions/Exemptions for Medicare-Certified Providers Affected by Hurricane Harvey
The Centers for Medicare & Medicaid Services (CMS) is granting exceptions under certain Medicare quality reporting and value-based purchasing programs without having to submit an extraordinary circumstances exception request if they are located in one of the Texas counties or...
Immune-Related Toxicity and Time to Treatment Failure With Nivolumab Plus Ipilimumab in Advanced Melanoma
As reported in JAMA Oncology by Shoushtari et al, a single-center experience has shown a very high rate of clinically significant immune-related adverse events with nivolumab (Opdivo) plus ipilimumab (Yervoy) for advanced melanoma. Their findings suggest that the full course of four doses of...
Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma
The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported by Weller et al...
Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Breast Cancer
The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by ...
ASTRO Welcomes New Officers to Board of Directors
THE MEMBERS of the American Society for Radiation Oncology (ASTRO) have elected three new officers to ASTRO’s Board of Directors and three members to serve on the medical society’s Nominating Committee. The newly elected President-Elect, Health Policy Council Vice-Chair, Science Council Vice-Chair, ...
Expect Questions About Glioblastoma Symptoms
WITH THE MANY NEWS REPORTS about Senator John McCain being diagnosed with glioblastoma, patients may be asking if symptoms such as headaches and vision or speech problems should signal the need for screening or diagnostic tests. “There has never been any suggestion that doing routine screening,...
‘Substantial Improvements’ in the Treatment of Glioblastoma
NEWS ARTICLES about Senator John McCain’s diagnosis of glioblastoma accurately describe glioblastoma as aggressive and having a poor prognosis. But as Walter J. Curran, Jr, MD, pointed out in one of those reports, “substantial improvements in surgical approaches” have enabled more patients to...
Fever Therapy for Cancer
Fever therapy became firmly established as a significant therapeutic modality during the first decades of the 20th century. Physicians in this era believed the heat of a fever assisted in the control of numerous infections by killing the infective organism as it traveled through the bloodstream....
NCCN Foundation Announces Fifth 2017 Young Investigator Award
THE NCCN Foundation has granted its fifth Young Investigator Award for the 2017 cycle to Liqin Zhu, PhD, of St. Jude Children’s Research Hospital/ University of Tennessee Health Science Center, for the study titled, “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery.”...
Control
Many Type A personalities deal with problems by controlling all aspects of the problem. Sometimes this works. Sometimes it works for a while. Sometimes it doesn’t work at all. The health-care system—hospitals, clinics, and doctors’ offices—have policies (specific office hours and strict...
Cancer Has Robbed Me of a Life I Loved
I always knew cancer was a real possibility for me. Both my mother and father died of the disease—my mother of lung cancer and my father of bone cancer—so when I started having chronic throat and chest infections, I was diligent about seeking immediate medical attention and felt relieved each time ...
Clinical Trials Actively Recruiting Patients With Prostate Cancer
THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with prostate cancer. These studies highlight noninvasive imaging, gene therapy, allogeneic bone marrow transplant, selective androgen receptor modulators, Vitamin D3...
To the Last Drop
It was 2:15 PM, and my afternoon clinic had not yet begun. The morning had been particularly trying as a result of disastrous clinical developments for two of my long-standing patients. Jessica had metastatic breast cancer, and I had been taking care of her for 7 years. Multiple lines of...
